obesity drug maritide news - Search News

What's Next for Amgen Obesity Drug

The New York Times on MSN · 1d

New Obesity Drug MariTide Helps Patients Lose Up to 20% of Weight, Early Data Shows

The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 percent of their weight in a year. The drug, MariTide, is given by injection once a month,

CNBC on MSN · 1d

Amgen says obesity drug caused up to 20% weight loss after a year, with no plateau

The results shed light on how MariTide may measure up to weight loss injections from Novo Nordisk and Eli Lilly and other experimental treatments.

What's Next for Amgen Obesity Drug After Investors Disappointed by Results

Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.

FierceBiotech1d

Amgen's monthly obesity drug matches competition in phase 2, but investors are unimpressed

MariTide, which like Eli Lilly’s Zepound is a dual agonist of the GLP-1 and GIP receptors, demonstrated an average weight ...

18h

Amgen’s MariTide: Hold Rating Amid Efficacy and Safety Concerns in Obesity Treatment

Mizuho Securities analyst Salim Syed has maintained their neutral stance on AMGN stock, giving a Hold rating yesterday.Don't Miss our Black ...

1d

Amgen stock slips as obesity drug study disappoints Wall Street

Amgen (AMGN) fell sharply during Tuesday's intraday trading following the release of phase two trial results for its monthly ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results